182 related articles for article (PubMed ID: 36776524)
1. Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance.
Peng G; Wang C; Wang H; Qu M; Dong K; Yu Y; Jiang Y; Gan S; Gao X
Oncoimmunology; 2023; 12(1):2173422. PubMed ID: 36776524
[TBL] [Abstract][Full Text] [Related]
2. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
[No Abstract] [Full Text] [Related]
3. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.
Huang H; Wang C; Liu F; Li HZ; Peng G; Gao X; Dong KQ; Wang HR; Kong DP; Qu M; Dai LH; Wang KJ; Zhou Z; Yang J; Yang ZY; Cheng YQ; Tian QQ; Liu D; Xu CL; Xu DF; Cui XG; Sun YH
Clin Cancer Res; 2018 Sep; 24(18):4612-4626. PubMed ID: 29691294
[No Abstract] [Full Text] [Related]
5. Knockdown of HMGB1 inhibits the crosstalk between oral squamous cell carcinoma cells and tumor-associated macrophages.
Wen J; Yin P; Su Y; Gao F; Wu Y; Zhang W; Chi P; Chen J; Zhang X
Int Immunopharmacol; 2023 Jun; 119():110259. PubMed ID: 37141670
[TBL] [Abstract][Full Text] [Related]
6. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
7. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
8. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer.
El-Kenawi A; Dominguez-Viqueira W; Liu M; Awasthi S; Abraham-Miranda J; Keske A; Steiner KK; Noel L; Serna AN; Dhillon J; Gillies RJ; Yu X; Koomen JM; Yamoah K; Gatenby RA; Ruffell B
Cancer Res; 2021 Nov; 81(21):5477-5490. PubMed ID: 34301759
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
10. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
Sakurai T; Yada N; Hagiwara S; Arizumi T; Minaga K; Kamata K; Takenaka M; Minami Y; Watanabe T; Nishida N; Kudo M
Cancer Sci; 2017 Oct; 108(10):1996-2003. PubMed ID: 28777492
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.
Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L
Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
13. Increased tumor-associated macrophages in the prostate cancer microenvironment predicted patients' survival and responses to androgen deprivation therapies in Indonesian patients cohort.
Yuri P; Shigemura K; Kitagawa K; Hadibrata E; Risan M; Zulfiqqar A; Soeroharjo I; Hendri AZ; Danarto R; Ishii A; Yamasaki S; Yan Y; Heriyanto DS; Fujisawa M
Prostate Int; 2020 Jun; 8(2):62-69. PubMed ID: 32647642
[TBL] [Abstract][Full Text] [Related]
14. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
Brown NE; Jones A; Hunt BG; Waltz SE
Prostate; 2022 Nov; 82(15):1422-1437. PubMed ID: 35860905
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer.
Riahi MM; Sistani NS; Zamani P; Abnous K; Jamialahmadi K
Neoplasma; 2017; 64(5):732-737. PubMed ID: 28592125
[TBL] [Abstract][Full Text] [Related]
17. Gankyrin promotes osteosarcoma tumorigenesis by forming a positive feedback loop with YAP.
Cheng L; Wu B; Zhang L; Bian E; An R; Yu S; Liu W; Xiong Z
Cell Signal; 2020 Jan; 65():109460. PubMed ID: 31678253
[TBL] [Abstract][Full Text] [Related]
18. Nur77 suppression facilitates androgen deprivation-induced cell invasion of prostate cancer cells mediated by TGF-β signaling.
Wu J; Sun H; Yang X; Sun X
Clin Transl Oncol; 2018 Oct; 20(10):1302-1313. PubMed ID: 29594945
[TBL] [Abstract][Full Text] [Related]
19. IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer.
Wang D; Cheng C; Chen X; Wang J; Liu K; Jing N; Xu P; Xi X; Sun Y; Ji Z; Zhao H; He Y; Zhang K; Du X; Dong B; Fang Y; Zhang P; Qian X; Xue W; Gao WQ; Zhu HH
Adv Sci (Weinh); 2023 Jun; 10(17):e2206889. PubMed ID: 37092583
[TBL] [Abstract][Full Text] [Related]
20. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
